TARDBP and frontotemporal dementia: However, only small patient numbers (two ALS [40], five FTD‐TDP type A and two FTD‐TDP type B cases [39]) have been examined so far, and these studies did not reveal the total phosphorylation level across TDP‐43 molecules, hence it is still unclear which fraction of TDP‐43 molecules is truly “hyperphosphorylated” in disease, since phosphosite occupancy can only be quantitatively determined through targeted proteomics.